Press Releases Nektar Therapeutics

Equities

NKTR

US6402681083

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.46 ^USD	+10.61%		+7.35%	+158.41%

Apr. 24	Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases	CI
Mar. 19	Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nektar Therapeutics : SCHEDULE 14A	Apr. 26	PU
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference	Mar. 25	AQ
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	Mar. 22	PR
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	Mar. 05	PR
Nektar: Q4 Earnings Snapshot	Mar. 04	AQ
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX	Mar. 04	PR
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 27	PR
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets	Feb. 26	PR
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA	Jan. 03	PR
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology Annual Meeting	Dec. 12	AQ
Nektar Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	Nov. 27	PU
Nektar: Q3 Earnings Snapshot	Nov. 07	AQ
Nektar Therapeutics Reports Third Quarter 2023 Financial Results	Nov. 07	PR
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets	23-10-31	PR
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress	23-10-16	AQ
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress	23-10-13	PR
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy	23-10-02	PR
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer	23-09-27	PR
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis	23-09-13	PR
Nektar Therapeutics : Termination of Material Agreement - Form 8-K	23-09-08	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Nektar Therapeutics

Equities

NKTR

US6402681083

Press Releases

Filters